Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Hypertension is a common cardiovascular risk factor leading to heart failure (HF), coronary artery disease, stroke, peripheral artery disease and chronic renal insufficiency. Hypertensive heart disease can manifest as many cardiac arrhythmias, most commonly being atrial fibrillation (AF). Both supraventricular and ventricular arrhythmias may occur in hypertensive patients, especially in those with left ventricular hypertrophy (LVH) or HF. Also, some of the antihypertensive drugs commonly used to reduce blood pressure, such as thiazide diuretics, may result in electrolyte abnormalities (e.g. hypokalaemia, hypomagnesemia), further contributing to arrhythmias, whereas effective control of blood pressure may prevent the development of the arrhythmias such as AF. In recognizing this close relationship between hypertension and arrhythmias, the European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) Council on Hypertension convened a Task Force, with representation from the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE), with the remit to comprehensively review the available evidence to publish a joint consensus document on hypertension and cardiac arrhythmias, and to provide up-to-date consensus recommendations for use in clinical practice. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and the patient in light of all of the circumstances presented by that patient.
['Lip|Gregory Y H|GYH|', 'Coca|Antonio|A|', 'Kahan|Thomas|T|', 'Boriani|Giuseppe|G|', 'Manolis|Antonis S|AS|', 'Olsen|Michael Hecht|MH|', 'Oto|Ali|A|', 'Potpara|Tatjana S|TS|', 'Steffel|Jan|J|', 'Marín|Francisco|F|', 'de Oliveira Figueiredo|Márcio Jansen|MJ|', 'de Simone|Giovanni|G|', 'Tzou|Wendy S|WS|', 'Chiang|Chern-En|CE|', 'Williams|Bryan|B|', '|||', 'Dan|Gheorghe-Andrei|GA|', 'Gorenek|Bulent|B|', 'Fauchier|Laurent|L|', 'Savelieva|Irina|I|', 'Hatala|Robert|R|', 'van Gelder|Isabelle|I|', 'Brguljan-Hitij|Jana|J|', 'Erdine|Serap|S|', 'Lovic|Dragan|D|', 'Kim|Young-Hoon|YH|', 'Salinas-Arce|Jorge|J|', 'Field|Michael|M|']
D000959:Antihypertensive Agents D001145:Arrhythmias, Cardiac D001794:Blood Pressure D032921:Consensus D003362:Cost-Benefit Analysis D016757:Death, Sudden, Cardiac D017048:Health Care Costs D006329:Heart Conduction System D006801:Humans D006973:Hypertension D018570:Risk Assessment D012307:Risk Factors D016896:Treatment Outcome
Hypertension Arrhythmias Atrial fibrillation Left ventricular hypertrophy EHRA consensus document